Preoperative administration of GnRH-a plus tibolone to premenopausal women with uterine fibroids: Evaluation of the clinical response, the immunohistochemical expression of PDGF, bFGF and VEGF and the vascular pattern

Steroids

Volumn 70, Issue 2, 2005, Pages 95-102

  Di Lieto, Andrea ^a,b   De Falco, Marianna ^a   Mansueto, Gelsomina ^a   De Rosa, Gaetano ^a   Pollio, Fabrizio ^a   Staibano, Stefania ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

Angiogenesis; bFGF; GnRH a; PDGF; Tibolone; Uterine leiomyomas; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; GONADORELIN DERIVATIVE; LEUPRORELIN; PLATELET DERIVED GROWTH FACTOR; TIBOLONE; VASCULOTROPIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; FIBROBLAST GROWTH FACTOR 2; GONADORELIN; PREGNANE DERIVATIVE; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MYOMECTOMY; PREMENOPAUSE; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; UTERUS MYOMA; VASCULARIZATION; BIOSYNTHESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; LEIOMYOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; UTERUS; UTERUS CANCER; VASCULAR SMOOTH MUSCLE;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PATHOLOGIC; NORPREGNENES; PLATELET-DERIVED GROWTH FACTOR; PREMENOPAUSE; UTERINE NEOPLASMS; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20544474030     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2004.10.008     Document Type: Article

References (30)

1. Vu K, Greenspan DL, Wu TC, Zacur HA, Kurkman RJ. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas. Hum Pathol 1998;29:359-63.
2. Palomba S, Affinito P, Tommaselli GA, Nappi C. A clinical trial on the effects of tibolone association with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 1998;70:111-8.
3. Lindsay PC, Shaw RW, Coelingh Bennink HJ, Kicovic P. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 1996;65(2):342-8.
4. Palomba S, Affinito P, Di Carlo C, Bifulco G, Nappi C. Long term administration of tibolone plus gonadotropin-releasing hormone agonist for treatment of uterine leiomyomas: effectiveness and effects on vasomotor symptoms, bone mass, and lipid profile. Fertil Steril 1999;72:889-95.
5. Palomba S, Pellicano M, Affinito P, Di Carlo C, Zullo F, Nappi C. Effectiveness of short-term administration of tibolone plus gonadotropin- releasing hormone analogue on the surgical outcome of laparoscopic myomectomy. Fertil Steril 2001;75(2):429-33.
6. Mizutani T, Sugihara A, Nakamuro K, Terada N. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate). J Clin Endocrinol Metab 1998;84(4):1253-5.
7. Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol 1994;170:1623-8.
8. Werner R. Mechanisms of angiogenesis. Nature 1997;386:671-4.
9. Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest 1993;69:508-71.
10. Anania CA, Stewart EA, Quade BJ, Hill JA, Nowak RA. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Pathol 1997;3(8):685-91.
11. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996;2(4):295-306.
12. Mirkin S, Mahony MC, Archer DF. Effect of tibolone and its metabolites on vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 mRNA in Ishikawa cells. Menopause 2004;11(1):82-8.
13. Detre S, Saccani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
14. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002;86:558-63.
15. Pickersgill A. GnRH agonists and add-back therapy: is there a perfect combination? Br J Obstet Gynaecol 1998;105:475-85.
16. Compston JH, Yamaguchi K, Croucher PI, Garraham NJ, Linday PC, Shaw RW. The effects of gonadotropin-releasing hormone agonist on iliac crest bone structure in women with endometriosis. Bone 1995;16:221-7.
17. Abulafia O, Kleinhaus K, Levi G, Lee YC, Sherer DM. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma. Gynecol Obstet Invest 2001;52:108-13.
18. Barbarisi A, Petillo O, Di Lieto A, Melone MAB, Margarucci S, Cannas M, et al. 17-β estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway. J Cell Physiol 2001;186:414-24.
19. Di Lieto A, De Rosa G, De Falco M, Iannotti F, Staibano S, Pollio F, et al. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment. Hum Pathol 2002;33(2):220-4.
20. Nowak RA. Identification of new therapies for leiomyomas: what in vitro studies can tell us. Clin Obstet Gynecol 2001;44(2):327-34.
21. Wu X, Blanck A, Olovsson M, Möller B, Linblom B. Expression of basic fibroblast growth factor (bFGF), FGF receptor 1 and FGF receptor 2 in uterine leiomyomas and myometrium during the menstrual cycle, after menopause and GnRH-a treatment. Acta Obstet Gynecol Scand 2001;80(6):497-504.
22. Di Lieto A, De Falco M, Staibano S, Iannotti F, Scaramellino M, Salvatore G, et al. Effects of gonadotropin-releasing hormone agonists on uterine volume and vasculature and on the immunohistochemical expression of basic fibroblast growth factor (bFGF) in uterine leiomyomas. Int J Gynecol Pathol 2003;22(4):353-8.
23. Tsai JC, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB and bFGF. J Neurosurg 1995;82:864-73.
24. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-32.
25. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995;80(6):1853-8.
26. Dixon D, Hong H, Haseman JK. Immnohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ Health Perspect 2000;108(Suppl 5):795-802.
27. Cordon-Cardo C, Vlodasky I, Haimovitz-Friedman A, Hicklin D, Fuks Z. Expression of basic fibroblast growth factor in normal human tissues. Lab Invest 1990;63(6):832-40.
28. Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas 2000;37:27-32.
29. Fedele L, Bianchi S, Raffaelli R, Zanconato R. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur L Obstet Gynecol Reprod Biol 2000;88:91-4.
30. Colacurci N, De Franciscis P, Cobellis L, Nazzaro G, De Placido G. Effects of hormone replacement therapy on postmenopausal uterine myoma. Maturitas 2000;35:167-73.